# ‚öîÔ∏è TRIAL INTELLIGENCE REPORT: NCT03067181 ‚öîÔ∏è

**Trial Name**: Active Surveillance, Bleomycin, Etoposide, Carboplatin or Ci...  
**Patient**: Ayesha Kiani (ID: ayesha_001)  
**Generated**: 2025-11-15T21:55:51.022914  
**Generated By**: Zo (Lead Commander)  
**Match Tier**: TOP_TIER  
**Composite Score**: 0.97/1.00  
**Eligibility Probability**: ~100%

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT03067181

---

## üî• WHY THIS MATTERS FOR AYESHA - CRITICAL ANALYSIS

**Status**: RECRUITING  
**Phase**: N/A  
**Sponsor**: Not specified

### ‚úÖ PIPELINE ASSESSMENT:

‚úÖ Status: RECRUITING
‚úÖ Gynecologic cancer trial match
‚úÖ Stage Iv eligible (patient: IVB)
- ‚úÖ INTERVENTIONAL treatment trial
- ‚úÖ 19 NYC metro location(s)
- ‚ö†Ô∏è Eligibility: ~100% (pending biomarkers)

**Semantic Similarity**: 0.000 (vector search match)

---

## üß¨ ELIGIBILITY ASSESSMENT FOR AYESHA

| Criterion | Ayesha's Status | Match | Action Required |
|-----------|-----------------|-------|-----------------|
| Stage IV epithelial ovarian | Stage IVB High-Grade Serous Ovarian Carcinoma (HGSOC) | ‚úÖ PASS | None |
| BRCA wildtype | Germline negative | ‚úÖ PASS | None |
| HER2 Status | UNKNOWN | ‚ö†Ô∏è GATE | HER2 IHC (3-5 days) |
| HRD Status | UNKNOWN | ‚ö†Ô∏è PENDING | MyChoice CDx (7-10 days) |
| Treatment Line | first-line | ‚úÖ PASS | None |
| Tissue Available | True | ‚úÖ PASS | None |
| Performance Status | ECOG 1 | ‚úÖ PASS | None |
| Geographic Access | NYC Metro | ‚úÖ PASS | None |

**Probability Ayesha Is Eligible**: ~100%  
**Calculation**: No specific restrictions (100% eligible)

---

## üéØ WHY THIS TRIAL IS A GOOD FIT FOR AYESHA (LLM Analysis)

Error calling Google Gemini API: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. 
* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 2, model: gemini-2.5-pro
Please retry in 7.674051545s. [links {
  description: "Learn more about Gemini API quotas"
  url: "https://ai.google.dev/gemini-api/docs/rate-limits"
}
, violations {
  quota_metric: "generativelanguage.googleapis.com/generate_content_free_tier_requests"
  quota_id: "GenerateRequestsPerMinutePerProjectPerModel-FreeTier"
  quota_dimensions {
    key: "model"
    value: "gemini-2.5-pro"
  }
  quota_dimensions {
    key: "location"
    value: "global"
  }
  quota_value: 2
}
, retry_delay {
  seconds: 7
}
]
Error calling Google Gemini API: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. 
* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 2, model: gemini-2.5-pro
Please retry in 7.674051545s. [links {
  description: "Learn more about Gemini API quotas"
  url: "https://ai.google.dev/gemini-api/docs/rate-limits"
}
, violations {
  quota_metric: "generativelanguage.googleapis.com/generate_content_free_tier_requests"
  quota_id: "GenerateRequestsPerMinutePerProjectPerModel-FreeTier"
  quota_dimensions {
    key: "model"
    value: "gemini-2.5-pro"
  }
  quota_dimensions {
    key: "location"
    value: "global"
  }
  quota_value: 2
}
, retry_delay {
  seconds: 7
}
]
Error calling Google Gemini API: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. 
* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 2, model: gemini-2.5-pro
Please retry in 7.674051545s. [links {
  description: "Learn more about Gemini API quotas"
  url: "https://ai.google.dev/gemini-api/docs/rate-limits"
}
, violations {
  quota_metric: "generativelanguage.googleapis.com/generate_content_free_tier_requests"
  quota_id: "GenerateRequestsPerMinutePerProjectPerModel-FreeTier"
  quota_dimensions {
    key: "model"
    value: "gemini-2.5-pro"
  }
  quota_dimensions {
    key: "location"
    value: "global"
  }
  quota_value: 2
}
, retry_delay {
  seconds: 7
}
]
Error calling Google Gemini API: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. To monitor your current usage, head to: https://ai.dev/usage?tab=rate-limit. 
* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 2, model: gemini-2.5-pro
Please retry in 7.674051545s. [links {
  description: "Learn more about Gemini API quotas"
  url: "https://ai.google.dev/gemini-api/docs/rate-limits"
}
, violations {
  quota_metric: "generativelanguage.googleapis.com/generate_content_free_tier_requests"
  quota_id: "GenerateRequestsPerMinutePerProjectPerModel-FreeTier"
  quota_dimensions {
    key: "model"
    value: "gemini-2.5-pro"
  }
  quota_dimensions {
    key: "location"
    value: "global"
  }
  quota_value: 2
}
, retry_delay {
  seconds: 7
}
]

---


## üö® CRITICAL DECISION TREE FOR AYESHA

START: Ayesha completes carboplatin + paclitaxel + bevacizumab (L1)
  ‚îÇ
  ‚îú‚îÄ‚Üí Biomarker Testing (if required)
  ‚îÇ    ‚îÇ
  ‚îÇ    ‚îî‚îÄ‚Üí **ELIGIBLE FOR TRIAL!** (pending results)
  ‚îÇ         Probability: ~100%
  ‚îÇ
  ‚îî‚îÄ‚Üí END: Enroll in NCT03067181

---

## üí° STRATEGIC IMPLICATIONS

### Best-Case Scenario:
‚úÖ Ayesha enrolls in NCT03067181
‚úÖ Access to experimental therapy
‚úÖ Close monitoring, expert care
**Probability**: ~100%

### Most Likely Scenario:
Ayesha completes screening and enrolls successfully (pending biomarkers)

### Challenge Scenario:
Screen failure due to biomarker requirements or other eligibility criteria

---

## üìã FULL ELIGIBILITY TEXT

### Eligibility Criteria
* There is no age limit for the low risk stratum (stage I ovarian immature teratoma and stage I non-seminoma or seminoma malignant GCT \[all sites\])
* Standard risk 1: Patients must be \< 11 years of age at enrollment
* Standard risk 2: Patients must be \>= 11 and \< 25 years of age at enrollment
* Patients enrolling on one of the low risk arms must be newly diagnosed with a stage I germ cell tumor; for the standard risk arms, patients must be newly diagnosed with malignant germ cell tumor (stage II or higher).

  * Histologic confirmation of a primary extracranial germ cell tumor in any of the categories outlined below is required of all patients at enrollment , with the following exceptions:

    * Among patients were initially diagnosed with completely resected non-seminoma malignant GCT and later recur during observation post surgery, a diagnostic biopsy is not required for enrollment if elevated tumor markers rise to \> 5 x upper limit of normal (ULN) on at least 2 measurements taken at least 1 week apart. The pathology report of initial surgery should be provided
    * Patients may be enrolled without histologic or cytologic confirmation in the rare case where there are exceptionally raised tumor markers (alpha fetoprotein \[AFP- ‚â• 500 ng/mL or HCG ‚â• 500 IU/L) and radiologic features consistent with GCT. In addition, the treating clinician must deem that the patient's tumor is not suitable for upfront resection and that a biopsy is not in the patient's best interest; or that there is a need to start therapy urgently
* Low risk immature teratoma (IT); site: ovarian; stage: any; grade: any; histology: pure immature teratoma, mixed immature and mature teratoma, (may contain microscopic foci of yolk sac tumor \[\< 3 mm\], but no other pathological evidence of MGCT); tumor markers: alpha-FP =\< 1,000 ng/mL, beta-HCG institutional normal; all ages
* Low risk stage I non-seminoma MGCT; site: ovarian, testicular, or extragonadal; stage: COG stage I, FIGO stage IA and IB, American Joint Committee on Cancer (AJCC) testicular stage IA, IB and IS; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); all ages
* Low risk stage I seminoma-MGCT; site: testicular; stage: COG stage I; AJCC testicular stage IA IB, and IS; histology: must contain only seminoma; may contain immature/mature teratoma; may NOT contain yolk sac tumor, embryonal carcinoma, or choriocarcinoma; all ages
* Standard risk 1 (SR1); site: ovarian, testicular, or extragonadal; stage: COG stage II-IV, FIGO stage IC-IV, (International Germ Cell Consensus Classification \[IGCCC\] criteria DO NOT apply); histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) \< 11
* Standard risk 2 (SR2)

  * Site: ovarian; stage: COG stage II, III, and III-X, FIGO stage IC, II and III; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age (years) \>= 11 and \< 25
  * Site: testicular; stage: COG stage II-IV, AJCC stage II, III, IGCCC good risk; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma: must be IGCCC good risk; post op: alpha-FP \< 1,000 ng/mL, beta-HCG \< 5,000 IU/mL and lactate dehydrogenase (LDH) \< 3.0 x normal; age (years) \>= 11 and \< 25
* Notes:

  * IGCCC criteria only apply to SR2 patients with a testicular primary tumor
  * Use post-op tumor marker levels to determine IGCCC risk group
  * Pure seminoma patients are not eligible for the standard risk arms of the study
  * For the low risk stage I non-seminoma MGCT and the standard risk arms, components of yolk sac tumor, embryonal carcinoma, or choriocarcinoma can be mixed with other forms of GCT, such as seminoma or mature or immature teratoma; if yolk sac tumor is the only malignant component present, then it must be deemed by the pathologist to be greater than a "microscopic component" of yolk sac tumor
* Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, 2 or 3; use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age
* Organ function requirements apply ONLY to patients who will receive chemotherapy (SR1 and SR2 patients)
* Adequate renal function defined as:
* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 (within 7 days prior to enrollment) OR
* A serum creatinine based on age/sex as follows (within 7 days prior to enrollment): (mg/dL)

  * 1 month to \< 6 months male: 0.4 female: 0.4
  * 6 months to \< 1 year male: 0.5 female: 0.5
  * 1 to \< 2 years male: 0.6 female: 0.6
  * 2 to \< 6 years male: 0.8 female: 0.8
  * 6 to \< 10 years male: 1 female: 1
  * 10 to \< 13 years male: 1.2 female: 1.2
  * 13 to \< 16 years: male: 1.5 female: 1.4
  * \>= 16 years male: 1.7 female: 1.4
* Total bilirubin =\< 2 x upper limit of normal (ULN) for age (within 7 days prior to enrollment)

  * Unless due to Gilbert's disease, malignant involvement of liver or vanishing bile duct syndrome
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 x upper limit of normal (ULN) (within 7 days prior to enrollment)

  * Unless due to Gilbert's disease, malignant involvement of liver or vanishing bile duct syndrome
* Peripheral absolute neutrophil count (ANC) \>= 750/mm\^3 (within 7 days prior to enrollment) AND
* Platelet count \>= 75,000/mm\^3 (within 7 days prior to enrollment)
* Patients enrolling on the standard risk arms must be medically fit to receive protocol treatment and with no contraindications to protocol treatment
* Eligibility criteria to participate in the pilot study of the AYA-Hears instrument (patient reported outcomes \[PROs\] of ototoxicity) Note: participants in group 1 will not receive AGCT1531 protocol-directed therapy; all other AYA-HEARS patients must be enrolled on the AGCT1531 SR2 arm in order to participate
* \>= 11 and \< 25 years old at enrollment
* Able to fluently speak and read English
* Has received prior cisplatin- or carboplatin-based chemotherapy regimen for malignancy including diagnoses other than germ cell tumor
* Followed for cancer or survivorship care at one of the following institutions:

  * Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
  * Dana Farber/Harvard Cancer Center
  * Hospital for Sick Children
  * Children's Hospital of Eastern Ontario
  * Oregon Health and Science University
  * Seattle Children's Hospital
  * Yale University * Patients with any diagnoses not listed including:

  * Stage I testicular cancer patients who have undergone primary RPLND (retroperitoneal lymph node dissection)
  * Pure ovarian or extragonadal dysgerminoma/seminoma
  * Pure mature teratoma
  * Pure immature teratoma with alpha-fetoprotein (AFP) \>= 1000 ng/mL
  * "Poor risk" GCT (age \>= 11 years old and COG stage IV ovarian, COG stage II- IV extragonadal, or IGCCC intermediate or poor risk testicular), or
  * Primary central nervous system (CNS) germ cell tumor
  * Germ cell tumor with somatic malignant transformation
  * Spermatocytic seminoma
* Patients must have had no prior systemic therapy for the current cancer diagnosis
* Patients must have had no prior radiation therapy with the exception of CNS irradiation of brain metastases; (this exception only applies to SR1 patients; any patients over age 11 with distant metastases to brain \[stage IV disease\] would be considered poor risk and therefore not eligible for this trial)
* Patients with significant, pre-existing co-morbid respiratory disease that contraindicate the use of bleomycin are ineligible for the standard risk arms of the trial
* Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs; a pregnancy test is required for female patients of childbearing potential; (this criteria applies ONLY to patients who will receive chemotherapy \[SR1 and SR2 patients\])
* Lactating females who plan to breastfeed their infants; (this criteria applies ONLY to patients who will receive chemotherapy \[SR1 and SR2 patients\])
* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation; (this criteria applies ONLY to patients who will receive chemotherapy \[SR1 and SR2 patients\])

---

## üìä TRIAL DESCRIPTION

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

---

## üè• LOCATION DETAILS

### NYC Metro Locations (Priority for Ayesha)

1. **Yale University** - New Haven, Connecticut
2. **Hackensack University Medical Center** - Hackensack, New Jersey
3. **Morristown Medical Center** - Morristown, New Jersey
4. **Saint Peter's University Hospital** - New Brunswick, New Jersey
5. **Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital** - New Brunswick, New Jersey
6. **Newark Beth Israel Medical Center** - Newark, New Jersey
7. **Saint Joseph's Regional Medical Center** - Paterson, New Jersey
8. **Maimonides Medical Center** - Brooklyn, New York
9. **NYU Langone Hospital - Long Island** - Mineola, New York
10. **Laura and Isaac Perlmutter Cancer Center at NYU Langone** - New York, New York
11. **Mount Sinai Hospital** - New York, New York
12. **NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center** - New York, New York
13. **Memorial Sloan Kettering Cancer Center** - New York, New York
14. **Montefiore Medical Center-Einstein Campus** - The Bronx, New York
15. **Montefiore Medical Center-Weiler Hospital** - The Bronx, New York
16. **Children's Hospital at Montefiore** - The Bronx, New York
17. **Montefiore Medical Center - Moses Campus** - The Bronx, New York
18. **Licking Memorial Hospital** - Newark, Ohio
19. **United Hospital Center** - Bridgeport, West Virginia

---

## ‚ö†Ô∏è CRITICAL GATES FOR AYESHA

‚úÖ No critical biomarker gates identified. Proceed with standard eligibility screening.

---

## ‚öîÔ∏è TACTICAL RECOMMENDATIONS

**Priority**: üî• **P0 - IMMEDIATE ACTION** (Eligibility: ~100%)

**Next Steps**:
1. **Order biomarker tests** (HER2 IHC, HRD if not done)
2. **Contact trial site** (within 48 hours)
3. **Pre-screen Ayesha** (get on coordinator's radar)
4. **Decision at Week 2**: Enroll if eligible
5. **Prepare medical records** (surgical report, pathology, CA-125 history)

**Expected Timeline**:
- Week 1: Complete L1 chemo (cycle 6)
- Week 2: Biomarker results available
- Week 3: Enroll in trial (if eligible) or proceed with SOC maintenance


---

## üéØ VALUE PROPOSITION

**WIN-WIN SCENARIO**:
- If eligible (100% chance) ‚Üí Access to experimental therapy
- If not eligible ‚Üí Gets proven SOC (PARP or bevacizumab maintenance)
- Either way, Ayesha receives appropriate care

**Risk-Benefit**: Low risk (pre-screening doesn't commit to enrollment), high reward (cutting-edge therapy)

---

## üìä PROVENANCE

**Generated By**: Zo (Lead Commander)  
**Pipeline Version**: v2.0 (Modular)  
**Data Source**: AstraDB vector search + Multi-stage filtering  
**Semantic Match Score**: 0.000  
**Composite Score**: 0.97 (Stage 1: 0.90, Stage 2: 0.95, Stage 3: 1.00, Stage 4: 1.00)  
**LLM Analysis**: Gemini gemini-2.5-pro  
**Quality**: ‚úÖ COMMANDER-GRADE INTELLIGENCE (Modular Pipeline v2.0)

---

**RESEARCH USE ONLY (RUO)** - This intelligence report is for research and strategic planning. All enrollment decisions must be reviewed by Ayesha's oncologist.

---

**‚öîÔ∏è FOR AYESHA!** ‚öîÔ∏è
